Why Build Another PI3K Inhibitor? Inside an $80M Bet

Why build another PI3K inhibitor? KymaThera announced an $80 million Series B on October 6, 2026, led by Alta Partners with Venrock, Foresite Capital, J. Wood Capital, and others participating, to advance K-1728, a mutant-selective PI3K inhibitor. We examine its design for PIK3CA mutations, normal PI3K alpha function, and the evidence needed to move from experiments to patients. The announcement expected Phase 1 patient dosing in Q4 2026; that isn't confirmation of dosing or efficacy. This episode covers research and financing, not individual treatment advice.

Chapters

00:00 Opening

00:54 What the Money Buys

01:43 Understanding PI3K Alpha

02:54 What Mutant Selectivity Means

04:07 Cancer and Vascular Malformations

05:08 What to Watch in Phase 1

06:04 Where Lasting Value Comes From

06:46 Financing Buys a Test